Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by KingWhatsion Oct 13, 2010 11:24am

569 Views

Post# 17558641

RE: Trading volume tells the tale

IMO, the folks who just invested 9 million in this stock will not be sitting on their hands. They are market makers and the recent action and share increase will be mostly because of their actions fueling expectations. Which may or may not pay off in real profits.

I bought to hold and that's what I'm doing for now. There's a nice profit waiting when the results come out or when the M & A action starts.

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX